{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:14:03Z","timestamp":1793834043146,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019668","name":"Pro Retina-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AR1432\/2-1"],"award-info":[{"award-number":["AR1432\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019347","name":"Tistou and Charlotte Kerstan Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Retinal degenerative diseases represent a complex global health problem due to their significant impact on patients\u2019 daily lives and their highly heterogeneous pathogenesis, which challenges therapeutic development. Despite this complexity, many diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), share common features, including disrupted proteostasis, oxidative stress, and inflammatory responses, eventually leading to photoreceptor (PR) degeneration and vision loss. The inhibition of valosin-containing protein (VCP) has emerged as a promising mutation-independent therapeutic strategy for RP. However, clinical translation requires rigorous validation in models that closely reflect human retinal physiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Organotypic retinal explants from porcine, macaque, and human donors were placed in an in vitro culture setup and treated with ML240, a selective VCP inhibitor, delivered either as a free compound or encapsulated in mPEG\n                      <jats:sub>5kDa<\/jats:sub>\n                      -cholane. Photoreceptor survival was assessed via TUNEL assay, outer nuclear layer (ONL) row quantification, and immunostaining. Retinal inflammation was evaluated by microglial staining. A dose\u2013response study was performed to determine safety margins across species, and additional retinal markers were used to assess the preservation of non-photoreceptor retinal cell populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Porcine retinal explants exhibited progressive photoreceptor degeneration under ex vivo conditions. Treatment with ML240, particularly when formulated with mPEG\n                      <jats:sub>5kDa<\/jats:sub>\n                      -cholane, significantly reduced photoreceptor cell death and microglial activation. Macaque and human explants exhibited minimal to no signs of degeneration. Treatment did not affect morphological or histological features of the explant, demonstrating the safety of ML240 in the primate retina.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      VCP inhibition via ML240 demonstrates an uncompromised safety profile in porcine, macaque, and human retinal explants. In addition, the neuroprotective activity of ML240 was evident in porcine tissue. Formulation with mPEG\n                      <jats:sub>5kDa<\/jats:sub>\n                      -cholane enhances the overall performance of the compound, supporting its use for future clinical application as a mutation-independent therapeutic approach for retinal degenerative diseases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04610-0","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:52:58Z","timestamp":1768006378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and neuroprotective efficacy of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo study"],"prefix":"10.1186","volume":"24","author":[{"given":"Ana-Cristina","family":"Almansa-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Armento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Petremann-Dum\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caliceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"S\u00fcsskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ueffing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Arango-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"4610_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123269","author":"M Ptito","year":"2021","unstructured":"Ptito M, Bleau M, Bouskila J. The retina: a window into the brain. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10123269.","journal-title":"Cells"},{"issue":"9","key":"4610_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nn0901-877","volume":"4","author":"RH Masland","year":"2001","unstructured":"Masland RH. The fundamental plan of the retina. Nat Neurosci. 2001;4(9):877\u201386.","journal-title":"Nat Neurosci"},{"key":"4610_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","volume":"65","author":"MT Pardue","year":"2018","unstructured":"Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res. 2018;65:50\u201376.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"4610_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ceo.13917","volume":"49","author":"M Georgiou","year":"2021","unstructured":"Georgiou M, Fujinami K, Michaelides M. Inherited retinal diseases: therapeutics, clinical trials and end points\u2014a review. Clin Exp Ophthalmol. 2021;49(3):270\u201388.","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"4610_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386.","journal-title":"Biostatistics"},{"issue":"4","key":"4610_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","volume":"57","author":"E Kim","year":"2023","unstructured":"Kim E, Yang J, Park S, Shin K. Factors affecting success of new drug clinical trials. Ther Innov Regul Sci. 2023;57(4):737\u201350.","journal-title":"Ther Innov Regul Sci"},{"key":"4610_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.pbr.2014.12.008","volume":"218","author":"JD Steeves","year":"2015","unstructured":"Steeves JD. Bench to bedside: challenges of clinical translation. Prog Brain Res. 2015;218:227\u201339.","journal-title":"Prog Brain Res"},{"issue":"1","key":"4610_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41583-019-0242-1","volume":"21","author":"T Baden","year":"2020","unstructured":"Baden T, Euler T, Berens P. Understanding the retinal basis of vision across species. Nat Rev Neurosci. 2020;21(1):5\u201320.","journal-title":"Nat Rev Neurosci"},{"key":"4610_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-12-384878-9.00006-6","volume":"100","author":"EL Fletcher","year":"2011","unstructured":"Fletcher EL, Jobling AI, Vessey KA, Luu C, Guymer RH, Baird PN. Animal models of retinal disease. Prog Mol Biol Transl Sci. 2011;100:211\u201386.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"4610_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1096-9861(20000814)424:1<1::AID-CNE1>3.0.CO;2-V","volume":"424","author":"S Haverkamp","year":"2000","unstructured":"Haverkamp S, W\u00e4ssle H. Immunocytochemical analysis of the mouse retina. J Comp Neurol. 2000;424(1):1\u201323.","journal-title":"J Comp Neurol"},{"issue":"7","key":"4610_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102392","volume":"9","author":"A Ort\u00edn-Mart\u00ednez","year":"2014","unstructured":"Ort\u00edn-Mart\u00ednez A, Nadal-Nicol\u00e1s FM, Jim\u00e9nez-L\u00f3pez M, Alburquerque-B\u00e9jar JJ, Nieto-L\u00f3pez L, Garc\u00eda-Ayuso D, et al. Number and distribution of mouse retinal cone photoreceptors: differences between an albino (Swiss) and a pigmented (C57\/BL6) strain. PLoS One. 2014;9(7):e102392.","journal-title":"PLoS One"},{"key":"4610_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109590","author":"TS Jakobsen","year":"2023","unstructured":"Jakobsen TS, Fabian-Jessing BK, Hansen S, Bek T, Askou AL, Corydon TJ. Porcine models of choroidal neovascularization: a systematic review. Exp Eye Res. 2023. https:\/\/doi.org\/10.1016\/j.exer.2023.109590.","journal-title":"Exp Eye Res"},{"key":"4610_CR13","doi-asserted-by":"crossref","unstructured":"Chandler, Samuelson, Mackay. Photoreceptor density of the domestic pig retina. Vet Ophthalmol. 1999;2(3):179\u201384.","DOI":"10.1046\/j.1463-5224.1999.00077.x"},{"key":"4610_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-024-10091-y","author":"VL Dufour","year":"2024","unstructured":"Dufour VL, Aguirre GD. Canine models of inherited retinal diseases: from neglect to well-recognized translational value. Mamm Genome. 2024. https:\/\/doi.org\/10.1007\/s00335-024-10091-y.","journal-title":"Mamm Genome"},{"issue":"2","key":"4610_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020344","volume":"13","author":"I Seah","year":"2022","unstructured":"Seah I, Goh D, Chan HW, Su X. Developing non-human primate models of inherited retinal diseases. Genes. 2022;13(2):344.","journal-title":"Genes"},{"issue":"13","key":"4610_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt9354","volume":"11","author":"R Ferla","year":"2025","unstructured":"Ferla R, Pugni E, Lupo M, Tiberi P, Fioretto F, Perota A, et al. Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models. Sci Adv. 2025;11(13):eadt9354.","journal-title":"Sci Adv"},{"issue":"2","key":"4610_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/02611929231157756","volume":"51","author":"LJ Marshall","year":"2023","unstructured":"Marshall LJ, Bailey J, Cassotta M, Herrmann K, Pistollato F. Poor translatability of biomedical research using animals\u2014a narrative review. Altern Lab Anim. 2023;51(2):102\u201335.","journal-title":"Altern Lab Anim"},{"issue":"1","key":"4610_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bcp.2013.08.006","volume":"87","author":"P McGonigle","year":"2014","unstructured":"McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2014;87(1):162\u201371.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4610_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0261192919840092","volume":"47","author":"S Schnichels","year":"2019","unstructured":"Schnichels S, Kiebler T, Hurst J, Maliha AM, L\u00f6scher M, Dick HB, et al. Retinal organ cultures as alternative research models. Altern Lab Anim. 2019;47(1):19\u201329.","journal-title":"Altern Lab Anim"},{"key":"4610_CR20","volume":"186","author":"W Xu","year":"2022","unstructured":"Xu W, Dong Y, Li Y, Hu Z, Paquet-Durand F, Jiao K. Organotypic retinal explant cultures from Macaque monkey. J Vis Exp. 2022;186:e64178.","journal-title":"J Vis Exp"},{"issue":"4","key":"4610_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjo.87.4.481","volume":"87","author":"D Carter","year":"2003","unstructured":"Carter D, Dick A. Lipopolysaccharide\/interferon-\u03b3 and not transforming growth factor \u03b2 inhibits retinal microglial migration from retinal explant. Br J Ophthalmol. 2003;87(4):481\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4610_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bjo.2010.181404","volume":"95","author":"N Niyadurupola","year":"2011","unstructured":"Niyadurupola N, Sidaway P, Osborne A, Broadway DC, Sanderson J. The development of human organotypic retinal cultures (HORCs) to study retinal neurodegeneration. Br J Ophthalmol. 2011;95(5):720\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4610_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-024-03422-8","volume":"31","author":"A Muller","year":"2025","unstructured":"Muller A, Sullivan J, Schwarzer W, Wang M, Park-Windhol C, Hasler PW, et al. High-efficiency base editing in the retina in primates and human tissues. Nat Med. 2025;31(2):490\u2013501.","journal-title":"Nat Med"},{"issue":"1","key":"4610_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep31184","volume":"6","author":"T Hasegawa","year":"2016","unstructured":"Hasegawa T, Muraoka Y, Ikeda HO, Tsuruyama T, Kondo M, Terasaki H, et al. Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration. Sci Rep. 2016;6(1):31184.","journal-title":"Sci Rep"},{"key":"4610_CR25","doi-asserted-by":"crossref","unstructured":"Arango-Gonzalez B, Sen M, Guarascio R, Ziaka K, del Amo EM, Hau K, et al. Inhibition of VCP preserves retinal structure and function in autosomal dominant retinal degeneration. BioRxiv. 2020:2020.11. 17.384669.","DOI":"10.1101\/2020.11.17.384669"},{"issue":"10","key":"4610_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101528","volume":"11","author":"M Sen","year":"2021","unstructured":"Sen M, Kutsyr O, Cao B, Bolz S, Arango-Gonzalez B, Ueffing M. Pharmacological inhibition of the VCP\/proteasome axis rescues photoreceptor degeneration in RHOP23H rat retinal explants. Biomolecules. 2021;11(10):1528.","journal-title":"Biomolecules"},{"issue":"6","key":"4610_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19768354.2016.1259181","volume":"20","author":"BK Yeo","year":"2016","unstructured":"Yeo BK, Yu S-W. Valosin-containing protein (VCP): structure, functions, and implications in neurodegenerative diseases. Anim Cells Syst. 2016;20(6):303\u20139.","journal-title":"Anim Cells Syst"},{"issue":"7","key":"4610_CR28","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.bbamcr.2008.01.015","volume":"1783","author":"RJ Braun","year":"2008","unstructured":"Braun RJ, Zischka H. Mechanisms of Cdc48\/VCP-mediated cell death\u2014from yeast apoptosis to human disease. Biochimica et Biophysica Acta (BBA). 2008;1783(7):1418\u201335.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"8","key":"4610_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001075","volume":"6","author":"A Griciuc","year":"2010","unstructured":"Griciuc A, Aron L, Roux MJ, Klein R, Giangrande A, Ueffing M. Inactivation of VCP\/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila. PLoS Genet. 2010;6(8):e1001075.","journal-title":"PLoS Genet"},{"issue":"2","key":"4610_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cmdc.201200520","volume":"8","author":"TF Chou","year":"2013","unstructured":"Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ. Structure\u2013activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013;8(2):297\u2013312.","journal-title":"ChemMedChem"},{"issue":"1","key":"4610_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2012.06.018","volume":"162","author":"S Salmaso","year":"2012","unstructured":"Salmaso S, Bersani S, Mastrotto F, Tonon G, Schrepfer R, Genovese S, et al. Self\u2010assembling nanocomposites for protein delivery: supramolecular interactions between PEG\u2010cholane and rh\u2010G\u2010CSF. J Control Release. 2012;162(1):176\u201384.","journal-title":"J Control Release"},{"key":"4610_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jconrel.2021.09.039","volume":"339","author":"M Sen","year":"2021","unstructured":"Sen M, Al-Amin M, Kickov\u00e1 E, Sadeghi A, Puranen J, Urtti A, et al. Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles. J Control Release. 2021;339:307\u201320.","journal-title":"J Control Release"},{"issue":"2","key":"4610_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0300-483X(75)90081-5","volume":"3","author":"PR Noel","year":"1975","unstructured":"Noel PR, Barnett KC, Davies RE, Jolly DW, Leahy JS, Mawdesley-Thomas LE, et al. The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit. Toxicology. 1975;3(2):143\u201369.","journal-title":"Toxicology"},{"key":"4610_CR34","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3389\/fimmu.2017.01930","volume":"8","author":"T Blank","year":"2017","unstructured":"Blank T, Goldmann T, Koch M, Amann L, Schon C, Bonin M, et al. Early Microglia Activation Precedes Photoreceptor Degeneration in a Mouse Model of CNGB1-Linked Retinitis Pigmentosa. Front Immunol. 2017;8:1930.","journal-title":"Front Immunol"},{"issue":"1","key":"4610_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010871","volume":"24","author":"K Johansson","year":"2023","unstructured":"Johansson K, Mohlin C. Microglia in cultured Porcine retina: qualitative immunohistochemical analyses of reactive microglia in the outer retina. Int J Mol Sci. 2023;24(1):871.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4610_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/imm.13479","volume":"166","author":"W Fan","year":"2022","unstructured":"Fan W, Huang W, Chen J, Li N, Mao L, Hou S. Retinal microglia: functions and diseases. Immunology. 2022;166(3):268\u201386.","journal-title":"Immunology"},{"key":"4610_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006897","volume":"13","author":"E Murenu","year":"2022","unstructured":"Murenu E, Gerhardt M-J, Biel M, Michalakis S. More than meets the eye: the role of microglia in healthy and diseased retina. Front Immunol. 2022;13:1006897.","journal-title":"Front Immunol"},{"key":"4610_CR38","doi-asserted-by":"publisher","DOI":"10.4199\/C00122ED1V01Y201412NGL003","volume-title":"Retinal glia","author":"A Reichenbach","year":"2015","unstructured":"Reichenbach A, Bringmann A. Retinal glia. Biota Publishing; 2015."},{"key":"4610_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pneurobio.2018.05.006","volume":"173","author":"G Rathnasamy","year":"2019","unstructured":"Rathnasamy G, Foulds WS, Ling E-A, Kaur C. Retinal microglia\u2013a key player in healthy and diseased retina. Prog Neurobiol. 2019;173:18\u201340.","journal-title":"Prog Neurobiol"},{"key":"4610_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.659843","volume":"15","author":"MA Dixon","year":"2021","unstructured":"Dixon MA, Greferath U, Fletcher EL, Jobling AI. The contribution of microglia to the development and maturation of the visual system. Front Cell Neurosci. 2021;15:659843.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"4610_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","volume":"61","author":"N Mehta","year":"2021","unstructured":"Mehta N, Robbins DA, Yiu G. Ocular inflammation and treatment emergent adverse events in retinal gene therapy. Int Ophthalmol Clin. 2021;61(3):151\u201377.","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"4610_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/glia.10149","volume":"40","author":"Y Imai","year":"2002","unstructured":"Imai Y, Kohsaka S. Intracellular signaling in M\u2010CSF\u2010induced microglia activation: role of Iba1. Glia. 2002;40(2):164\u201374.","journal-title":"Glia"},{"key":"4610_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exer.2012.08.012","volume":"104","author":"I Fernandez-Bueno","year":"2012","unstructured":"Fernandez-Bueno I, Fern\u00e1ndez-S\u00e1nchez L, Gayoso MJ, Garc\u00eda-Gutierrez MT, Pastor JC, Cuenca N. Time course modifications in organotypic culture of human neuroretina. Exp Eye Res. 2012;104:26\u201338.","journal-title":"Exp Eye Res"},{"key":"4610_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1343544","volume":"18","author":"A Bighinati","year":"2024","unstructured":"Bighinati A, Adani E, Stanzani A, D\u2019Alessandro S, Marigo V. Molecular mechanisms underlying inherited photoreceptor degeneration as targets for therapeutic intervention. Front Cell Neurosci. 2024;18:1343544.","journal-title":"Front Cell Neurosci"},{"key":"4610_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00417-004-0976-x","volume":"242","author":"F Roth","year":"2004","unstructured":"Roth F, Bindewald A, Holz FG. Keypathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol. 2004;242:710\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4610_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.pbr.2015.05.005","volume":"220","author":"H Levkovitch-Verbin","year":"2015","unstructured":"Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway in glaucoma: initiating and downstream mechanisms. Prog Brain Res. 2015;220:37\u201357.","journal-title":"Prog Brain Res"},{"key":"4610_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1208\/s12248-011-9253-1","volume":"13","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Gallo JM. The pharmacokinetic\/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011;13:111\u201320.","journal-title":"AAPS J"},{"key":"4610_CR48","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1023\/A:1013319408893","volume":"18","author":"M-L Chen","year":"2001","unstructured":"Chen M-L, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001;18:1645\u201350.","journal-title":"Pharm Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04610-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:07:24Z","timestamp":1769605644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04610-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4610"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04610-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving porcine and macaque tissues were performed in accordance with institutional guidelines and were approved by the local competent authority (Landratsamt T\u00fcbingen), under the registration number DE 08 416 1157 21, authorizing the use of category 1 animal by-products for research purposes (Regulation (EC) No. 1069\/2009; Regulation (EU) No. 142\/2011). Human tissue use was approved by the local ethics committee (Landratsamt T\u00fcbingen, reference number: 185\/2021BO2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}